It is well recognized that obesity has ballooned into a world-wide health concern, creating life-threatening metabolic disorders that reduce longevity and lower quality of life for millions. Recently, the FDA approved semaglutide and tirzepatide, two incretin mimetic drugs originally developed…

Obesity and type 2 diabetes go hand-in-hand, contributing to a cluster of biologic symptoms known as metabolic syndrome. Treating either symptom can profoundly improve the other, and the two are often tackled simultaneously. In its latest Standards of Care Supplement…